Blog Standard

Lorem ipsum dolor sit

We will participate in this year's digital version of the Bio-Europe - Europe's most important partnering conference in the biotech field. Looking forward to talk to you in individual 1-on-1 meetings from 26-29 October 2020! Find more information and the link for registration here: https://informaconnect.com/bioeurope/ ...

Read More

DyNAbind GmbHand Galapagos NV, a leading biotech company active in clinical stage drug discoveryand development, have entered a framework collaboration agreement for compoundscreening based on DyNAbind’s proprietary DNA-Encoded Library (DEL)technologies. This new longterm partnership aims at discovering novel drugcandidates for various indications, including inflammation and fibrosis. Michael Thompson, Ph.D, co-founder and CEO of DyNAbind, explains theimportance of this deal: “There’s nothing more exciting for us at...

Read More

Dresden/Barcelona, 18 May 2020. DyNAbind GmbH and Almirall, a leading skin-health focused pharmaceutical company based in Barcelona (Spain) have entered into a collaboration for compound screening based on DyNAbind’s proprietary DNA-encoded library (DEL) technology. This new partnership aims at discovering novel drug candidates for treating dermatological inflammation. Michael Thompson, Ph.D, co-founder and CEO of DyNAbind, explains the importance of this deal: “Relevant disease targets of dermatolocial...

Read More

Dresden, Germany, 27 April 2020 – DyNAbind GmbH and the University of Edinburgh have entered a new collaboration for the discovery of novel fragment- and small molecule-based drug candidates. More specifically, DyNAbind is working closely with the Centres for Cardiovascular Science and Inflammation Research based at The Queen's Medical Research Institute of the University of Edinburgh to find novel drug compounds for the treatment of...

Read More

We are happy to announce that DyNAbind GmbH has successfully completed the move of all lab and office equipment to our new premises! From February onwards, the new DyNAbind home base with more than 160 m2 lab and office space can now be found in the first floor of the BioInnovation Centre North wing in Johannstadt at Tatzberg 47, 01307 Dresden / Germany. Today we celebrated...

Read More

DyNAbind receives funding for a technology transfer project from the European Regional Development Fund (ERDF) DyNAbind is happy to announce a successful fundraising to support a technology transfer from the TU Dresden! This notice of grant from the Sächsiche Aufbaubank-Förderbank funds the project "Automated Hit Validation in Drug Research," helping us to acquire a patent from the TU Dresden, as well as partially funding a project for...

Read More

DyNAbind enters into a drug discovery collaboration with Columbia University Dresden, Germany, 19 June 2019 – DyNAbind GmbH has entered a collaboration with Columbia University for the discovery of new fragment- and small molecule-based drug candidates. DyNAbind is working with Professor Henry Colecraft and his group to discover novel drug candidates for multiple protein targets implicated in cystic fibrosis. Dr Michael Thompson, co-founder and CEO of DyNAbind,...

Read More

Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds   Ghent, Belgium, and Dresden, Germany - 3 July 2019 – Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR). The collaboration will combine ConfoBodyTM-enabled GPCRs with DyNAbind’s Dynamic DNA-encoded Library for the discovery of small molecule GPCR-modulating compounds. Under the...

Read More

We're happy to announce that DyNAbind has now closed its latest financing round with investment from the High-Tech Gründerfonds (HTGF), Technologie Gründerfonds Sachsen (TGFS) and the Technische Universität Dresden AG (TUDAG). HTGF and TGFS are institutional investors with strong track records in Germany, while TUDAG is demonstrating its confidence by investing in DyNAbind for a second time. To our new partners, we say "Welcome aboard!" Check out...

Read More

After about a year and a half of planning and development, we’re happy to announce that in addition to our existing discovery collaboration framework, DyNAbind is now offering a carefully selected portion of our DNA-Encoded Library collection as a kit for the do-it-yourself minded laboratory. Out of our collection of hundreds of millions of structures, we’ve selected about 370,000 fragment pairs that cover a broad...

Read More

We're proud to announce our drug discovery collaboration with OMass Therapeutics! Check out our press release below, and don't hesitate to get in touch with us to see how DyNAbind's proprietary DNA-Encoded Library technologies offer a better path to higher-quality, more relevant medicinal chemistry starting points, even for classically challenging targets! ...

Read More

DyNAbind was happy to be represented at the Spring 2019 American Chemcial Society meeting in sunny Orlando, Florida! CEO Mike Thompson was on hand to present DyNAbind’s innovative Dynamic Library technology platform and reveal some new data from an exciting collaboration with the lab of Prof. Stefan Diez on human kinesin 1 protein. In case you missed the event, check out our poster here, and don’t...

Read More
m

DyNAbind's Director of Research and Development, Francesco Reddavide, is in Ljubljana to present DyNAbind's technology platform and some recent screening results from our collection of over 125 million fragment and small molecule structures. If you're there, come say hi and learn how our platform can create a faster path to higher-quality, more relevant medicinal chemistry starting points for nearly any discovery campaign!...

Read More

Strategic Alliance for Discovery and Development of new Treatments for Cancer and Neurodegenerative Diseases   DyNAbind GmbH and CEITEC – Central European Institute of Technology announced that they have entered a strategic alliance for the discovery and development of drug candidates targeting human 14-3-3 protein complexes based on research performed in the labs of Dr. Jozef Hritz at CEITEC. 14-3-3 proteins play a crucial role in many cellular...

Read More

DyNAbind is happy to announce that it is now a member of biosaxony! In their own words biosaxony is the association of the biotechnology/medical technology sector in the region of Saxony. Its members represent the various companies, research institutes and lobbyists working in biotechnology and medtech and the related areas of engineering and material sciences in Saxony. It pulls the different strands of biotech and medtech...

Read More

On the road again, DyNAbind's Mike Thompson represented the company at flanders bio's 2018 Knowledge for Growth meeting in beautiful Gent. Over the day, Mike enjoyed the opportunity to make new contacts and get to know the local biotech ecosystem a bit better. Of course, he didn't arrive empty handed, bringing a poster showing how our proprietary DEL technologies can deliver superior results. Check out...

Read More

DyNAbind was represented at this year's Analytica trade fair in Munich. Over the four days of the event we had a great time making new contacts, spreading the word about DEL technologies and seeing what's new in the world of analytical equipment and methodology.   [caption id="attachment_320" align="aligncenter" width="940"] DyNAbind's team at Analytica 2018[/caption] ...

Read More

DyNAbind's second big event in October was a real honor - Out of over 200 teams that applied, we were one of the 41 selected to pitch at the HighTech Venture Days 2017. Located at the famous Gläserne Manufaktur right here in Dresden, we got to attend a world-class event and still sleep in our own beds at night! Over the two days of the...

Read More

DyNAbind's October travels began with a trip to Heidelberg for the 2017 European Business Development Conference from BioDeutschland. Our managing directors enjoyed two days in beautiful Heidelberg and the opportunity to pitch DyNAbind to an audience from pharma/biotech, investors and fellow entrepreneurs. While there we took part in a number of networking opportunities and enjoyed lively discussions on the current state of pharma innovation and...

Read More

Despite a block of cancelled flights and lost luggage, DyNAbind made it to the US for the Second Boston Symposium of Encoded Library Platforms. We enjoyed the variety of exciting talks and lively discussion, and presented a poster on using our Dynamic Library platform for affinity maturation on Carbonic Anhydrase II. Take a look here: DyNAbind_Boston_Poster_2017...

Read More

DyNAbind is now part of the Bundesministerium für Wirtschaft und Energie's INVEST program. This program allows private investors from the EU to receive a 20% rebate when investing at least 10,000 Euro in an approved innovative young start-up company. The rebate applies for up to 500,000 Euro of investment per calendar year. In the event that a participating company makes an exit, investors are also...

Read More